# A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

> **NCT06441812** · PHASE2 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Eosinophilic Asthma Patients

## Interventions

- **DRUG:** SHR-1703 Injection

## Key facts

- **NCT ID:** NCT06441812
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441812, "A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06441812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*